This AGC Biologics site in Yokohama, Japan, as depicted in June 2026, will offer one of the largest single-use bioreactors for a CDMO in Japan once operational in 2027. The new facility will also benefit from close collaboration with the 1,000+ scientists at the AGC Yokohama Technical Center and the AGC Biologics facility in Chiba, Japan.
This AGC Biologics site in Yokohama, Japan, as depicted in June 2026, will offer one of the largest single-use bioreactors for a CDMO in Japan once operational in 2027. The new facility will also benefit from close collaboration with the 1,000+ scientists at the AGC Yokohama Technical Center and the AGC Biologics facility in Chiba, Japan.